|
Name |
Palmarumycin B1
|
Molecular Formula | C20H16O8 | |
IUPAC Name* |
(1R,5S,6S,7S,8S,9R)-5,7,8,9-tetrahydroxyspiro[11-oxatricyclo[4.4.1.01,6]undec-3-ene-10,3'-2,4-dioxatricyclo[7.3.1.05,13]trideca-1(12),5,7,9(13),10-pentaene]-2-one
|
|
SMILES |
C1=CC2=C3C(=C1)OC4([C@@H]([C@H]([C@@H]([C@@]56[C@@]4(O5)C(=O)C=C[C@@H]6O)O)O)O)OC3=CC=C2
|
|
InChI |
InChI=1S/C20H16O8/c21-12-7-8-13(22)19-18(12,28-19)16(24)15(23)17(25)20(19)26-10-5-1-3-9-4-2-6-11(27-20)14(9)10/h1-8,12,15-17,21,23-25H/t12-,15-,16-,17+,18-,19-/m0/s1
|
|
InChIKey |
VECNRBBJPZNVDG-SBIIOWDGSA-N
|
|
Synonyms |
Palmarumycin B1; CHEMBL3342626
|
|
CAS | NA | |
PubChem CID | 101888369 | |
ChEMBL ID | CHEMBL3342626 |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 384.3 | ALogp: | -0.5 |
HBD: | 4 | HBA: | 8 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 129.0 | Aromatic Rings: | 6 |
Heavy Atoms: | 28 | QED Weighted: | 0.462 |
Caco-2 Permeability: | -5.61 | MDCK Permeability: | 0.00002920 |
Pgp-inhibitor: | 0.005 | Pgp-substrate: | 0.984 |
Human Intestinal Absorption (HIA): | 0.299 | 20% Bioavailability (F20%): | 0.591 |
30% Bioavailability (F30%): | 0.946 |
Blood-Brain-Barrier Penetration (BBB): | 0.52 | Plasma Protein Binding (PPB): | 86.06% |
Volume Distribution (VD): | 0.474 | Fu: | 2.88% |
CYP1A2-inhibitor: | 0.04 | CYP1A2-substrate: | 0.869 |
CYP2C19-inhibitor: | 0.028 | CYP2C19-substrate: | 0.727 |
CYP2C9-inhibitor: | 0.015 | CYP2C9-substrate: | 0.063 |
CYP2D6-inhibitor: | 0.006 | CYP2D6-substrate: | 0.182 |
CYP3A4-inhibitor: | 0.025 | CYP3A4-substrate: | 0.426 |
Clearance (CL): | 8.828 | Half-life (T1/2): | 0.682 |
hERG Blockers: | 0.005 | Human Hepatotoxicity (H-HT): | 0.982 |
Drug-inuced Liver Injury (DILI): | 0.978 | AMES Toxicity: | 0.984 |
Rat Oral Acute Toxicity: | 0.579 | Maximum Recommended Daily Dose: | 0.021 |
Skin Sensitization: | 0.892 | Carcinogencity: | 0.958 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.037 |
Respiratory Toxicity: | 0.88 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC001999 | 0.784 | D0Q3VE | 0.273 | ||||
ENC003195 | 0.736 | D08CCE | 0.252 | ||||
ENC003196 | 0.717 | D06TJJ | 0.238 | ||||
ENC003197 | 0.629 | D0AZ8C | 0.229 | ||||
ENC003239 | 0.606 | D01TNW | 0.227 | ||||
ENC002330 | 0.606 | D08DFX | 0.221 | ||||
ENC002185 | 0.602 | D06ALD | 0.219 | ||||
ENC003238 | 0.558 | D09LDR | 0.214 | ||||
ENC003198 | 0.554 | D00JRA | 0.212 | ||||
ENC001988 | 0.524 | D04BNP | 0.211 |